PD-ECGF as biomarker of cancer
The present invention corresponds to the field of cancer and is related to predicting cancer detection, diagnosis, monitoring and prediction of response to treatment, in particular platelet derived-endothelial cell growth factor (PD-ECGF) levels for their use as a potential value in monitoring disease evolution and predicting response to anti-angiogenic treatment.
1. A method for providing an anti-angiogenic treatment to a subject suffering from cancer, wherein said anti-angiogenic treatment is not doxorubicin or interferon therapy and wherein the cancer is renal cell carcinoma or colorectal cancer, the method comprising:
(i) obtaining a sample from the subject, wherein the sample is a tissue sample or a biological fluid sample, and wherein the tissue sample is a sample from a tumor or wherein the biological fluid sample is a sample of blood, serum or plasma;
(ii) determining the level of PD-ECGF in the sample from said subject;
(iii) comparing the level obtained in (ii) to a reference value, and
(iv) administering an anti-angiogenic treatment to a subject having a decreased level of PD-ECGF when compared to the reference value, wherein said anti-angiogenic treatment is not doxorubicin or interferon therapy.
2. A method according to claim 1 , wherein response is measured as early progression of cancer.
3. A method according to claim 1 , wherein the anti-angiogenic treatment is initiated after the determination of the levels of PD-ECGF.
4. The method of claim 1 , wherein the tumor is the primary tumor or a metastasis.
5. The method according to claim 1 , wherein the level of PD-ECGF determined is the PD-ECGF protein level.
6. The method according to claim 5 , wherein the PD-ECGF protein level is determined by immunohistochemistry, by ELISA, or by western blot.
7. The method according to claim 1 , wherein the anti-angiogenic treatment comprises an anti-VEGF agent.
8. The method according to claim 7 , wherein the anti-VEGF agent is an anti-VEGF antibody.
9. The method according to claim 8 , wherein the anti-VEGF agent is bevacizumab.
10. The method according to claim 1 , wherein the anti-angiogenic treatment comprises an agent which inhibits the tyrosine kinases stimulated by VEGF.
11. The method according to claim 10 , wherein the agent which inhibits the tyrosine kinases stimulated by VEGF is sunitinib.
12. The method according to claim 1 , wherein the anti-angiogenic treatment comprises a VEGFR2 blocking antibody.
13. The method according to claim 12 , wherein the VEGFR2 blocking antibody is DC101.
14. The method according to claim 1 wherein the cancer is renal cell carcinoma.
15. The method according to claim 1 wherein the cancer is colorectal cancer.